{"disease":{"id":"actinic-keratosis-ak","name":"actinic keratosis ak"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01926496","title":"Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":485,"lead_sponsor_name":"LEO Pharma","has_results":true},{"nct_id":"NCT03727074","title":"Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":462,"lead_sponsor_name":"Sol-Gel Technologies, Ltd.","has_results":false},{"nct_id":"NCT03116698","title":"A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Dr. Reddy's Laboratories Limited","has_results":true},{"nct_id":"NCT07290959","title":"Indoor Daylight Photodynamic Therapy is an Effective, First-line Treatment for AK, But Its Feasibility is Limited by the Time Required for the Illumination (2 Hours). Our Objective Was to Evaluate the Efficacy of Idl-PDT With an Illumination Time of 1 Hour Versus 2 Hours in the Treatment of Scalp AK","phase":"NA","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"San Salvatore Hospital of L'Aquila","has_results":false},{"nct_id":"NCT07286318","title":"A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Marissa Lobl","has_results":false},{"nct_id":"NCT06648447","title":"Investigation of the Efficacy and Tolerability of Topical Applied Tirbanibulin on Actinic Keratoses With Downward-directed Proliferation Patterns","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Thomas Dirschka","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}